Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China
Authors
Keywords
-
Journal
BMC CANCER
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1186/s12885-023-11584-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
- (2023) Silvia Novello et al. JOURNAL OF CLINICAL ONCOLOGY
- T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
- (2022) Alexander X. Lozano et al. NATURE MEDICINE
- Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study
- (2022) Qi Mei et al. Journal for ImmunoTherapy of Cancer
- Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic
- (2022) Doran Ksienski et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan
- (2022) Makoto Hibino et al. Journal of Thoracic Oncology
- A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors
- (2022) Mengni Guo et al. JOURNAL OF IMMUNOTHERAPY
- Immune-Related Adverse Events Among COVID-19–Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade
- (2022) Adam J. Widman et al. Journal of the National Comprehensive Cancer Network
- At the Crossroads: COVID-19 and Immune Checkpoint Blockade for Cancer
- (2021) Marina Chiara Garassino et al. Cancer Immunology Research
- Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
- (2021) P. Grivas et al. ANNALS OF ONCOLOGY
- Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study
- (2021) Sheena Bhalla et al. LUNG CANCER
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.
- (2020) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
- (2020) Lennard Y W Lee et al. LANCET
- Cytokine release syndrome in severe COVID-19
- (2020) John B. Moore et al. SCIENCE
- Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers
- (2020) Jia Luo et al. Cancer Discovery
- Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2020) Tuo Deng et al. JAMA Oncology
- Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness
- (2020) Anton Pak et al. Frontiers in Public Health
- Lymphocyte Subset Counts in COVID ‐19 Patients: A Meta‐Analysis
- (2020) Wei Huang et al. CYTOMETRY PART A
- A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab
- (2020) Lucia Bonomi et al. Journal of Thoracic Oncology
- Determinants of COVID-19 disease severity in patients with cancer
- (2020) Elizabeth V. Robilotti et al. NATURE MEDICINE
- Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
- (2020) Sreya Bagchi et al. Annual Review of Pathology-Mechanisms of Disease
- A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients
- (2019) Alessio Cortellini et al. SEMINARS IN ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors
- (2018) Karthik Suresh et al. Journal of Thoracic Oncology
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started